Tag: onychomycosis treatment market growth

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Onychomycosis Treatment Market Size During 2025–2029?

The onychomycosis treatment market size has experienced robust growth in recent years. Its value is anticipated to increase from $3.65 billion in 2024 to $3.91 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.1%. The expansion observed in the historic period is largely due to factors such as increasing fungal infections, an aging population, greater public awareness, the rising prevalence of onychomycosis, and growing disposable incomes.

The onychomycosis treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $5.1 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this growth during the forecast period include an aging global population, the expansion of telemedicine, the rise of combination therapies, improved access to healthcare services, evolving lifestyles and environmental influences, and the growing incidence of diabetes. Key trends expected in the same period involve advancements in dermatology, innovations in drug delivery, the development of personalized treatment plans, progress in topical treatments, the integration of digital health solutions, and the increasing use of laser therapy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

Which Factors And Drivers Are Influencing The Onychomycosis Treatment Market In 2025?

The rising prevalence of fungal infections is projected to fuel the expansion of the onychomycosis treatment market in the future. Fungal infections are illnesses stemming from different types of fungi, which can impact various areas of the body or lead to particular ailments. Onychomycosis, a common fungal nail infection, is commonly addressed using either systemic oral antifungal drugs or localized topical antifungal remedies to eradicate the fungal presence and encourage the regeneration of healthy nails. For example, in September 2023, data from the UK Health Security Agency, a government entity in the UK, indicated that the SGSS recorded 2,265 reported instances of yeast-related bloodstream infections (BSI) in England during 2022. The overall rate of yeast BSI incidence saw a minor increase, reaching 4.0 per 100,000 population, an uptick from 3.8 per 100,000 in 2021. The primary three yeast species identified in blood samples were Candida albicans (40%), Nakaseomyces glabratus (previously known as Candida glabrata, 29%), and Candida parapsilosis (13%). Consequently, the escalating frequency of fungal infections is propelling the expansion of the onychomycosis treatment market.

What Are The Segment Types Shaping The Onychomycosis Treatment Market?

The onychomycosis treatmentmarket covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types

2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy

3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Which Competitive Trends Are Defining The Onychomycosis Treatment Market Structure?

Key companies within the onychomycosis treatment market are concentrating on developing innovative products, such as MOB-015, and obtaining regulatory approvals to achieve a market advantage. For instance, in June 2023, Moberg Pharma AB, a Sweden-based pharmaceutical entity, secured approval for MOB-015 in the European Union for the treatment of mild to moderate fungal nail infections in adults. This European Union approval represents the first global marketing authorization for this advanced onychomycosis medication. Supporting MOB-015’s approval, two Phase 3 trials showcased an improved mycological cure (76% versus up to 42% for comparators) and a significantly higher total cure rate than the vehicle, all without any serious adverse effects. The topical terbinafine formulation, MOB-015, facilitates effective terbinafine concentrations reaching the nail and nail bed, thereby mitigating the systemic exposure risks associated with oral terbinafine treatment.

Who Are The Primary Competitors In The Global Onychomycosis Treatment Market?

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

How Do Regional Market Performances Compare Within The Onychomycosis Treatment Industry?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Onychomycosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

Browse Through More Reports Similar to the Global Onychomycosis Treatment Market 2025, By The Business Research Company

Generic Pharmaceuticals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

Ethical Pharmaceuticals Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ethical-pharmaceuticals-global-market-report

Biopharmaceuticals Contract Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Onychomycosis Treatment Market Through 2034?

In recent times, there has been a marked increase in the size of the market for onychomycosis treatment. The market, which was worth $3.65 billion in 2024, is projected to expand to $3.91 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.1%. The notable growth in the previous period could be ascribed to factors such as the surge in fungal infections, an aging population, enhanced public awareness, a heightened incidence of onychomycosis, and ascending disposable incomes.

Anticipated robust expansion is on the horizon for the onychomycosis treatment market, with a projected growth to$5.1 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.9%. This predicted growth during the forecast period can be credited to various factors such as the increasing elderly population, the broadening of telemedicine, the advent of combination therapies, improved access to healthcare, evolving lifestyles, and environmental factors, as well as the rising incidence of diabetes. Notable trends to look out for within this forecast period include advancements in dermatology, innovative drug delivery techniques, the rise of personalized treatment regimens, progress in topical treatment methods, the uprising of digital health solutions and the development of laser therapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

Which Primay Drivers Are Accelerating Growth in the Onychomycosis Treatment Market?

The rise in fungal infections is predicted to provide impetus for the expansion of the onychomycosis treatment market. These infections, caused by different types of fungi, impact various parts of the body and lead to specific conditions. One such condition, Onychomycosis, a fungal nail infection, is usually addressed with oral antifungal drugs or local antifungal solutions to eradicate the underlying fungal proliferation and promote the growth of a healthy nail. As an example, in September 2023, the UK Health Security Agency, a governmental agency in the UK, registered 2,265 cases of bloodstream infections (BSI) due to yeast in England in 2022, as tracked by the SGSS. The overall prevalence rate of BSI due to yeast saw a slight rise to 4.0 per 100,000 population, an increase from 3.8 per 100,000 in 2021. The three yeast species most commonly found in blood samples included Candida albicans (40%), Nakaseomyces glabratus (formerly known as Candida glabrata, 29%), and Candida parapsilosis (13%). Hence, the surge in fungal infections is a key driver for the onychomycosis treatment market’s growth.

Which Primary Segments of the Onychomycosis Treatment Market Are Driving Growth and Industry Transformations?

The onychomycosis treatmentmarket covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis; White Superficial Onychomycosis; Proximal Sublingual Onychomycosis; Candida Onychomycosis; Other Types

2) By Treatment Type: Drugs; Laser Therapy; Photodynamic Therapy

3) By Age Group: 0 To 18 Years; 18 To 39 Years; 40 To 64 Years; 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Onychomycosis Treatment Market?# Market?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Onychomycosis Treatment Industry Dynamics?

Leading companies in the onychomycosis treatment market are striving to maintain their competitive edge by producing innovative new products such as MOB-015 and seeking their approval from government agencies. For example, in June 2023, Moberg Pharma AB, a pharmaceutical company based in Sweden, secured approval for MOB-015 from the European Union. This approval signified the inaugural global marketing authorization for the pioneering onychomycosis medication. MOB-015’s approval was backed by results from two Phase 3 tests that exhibited enhanced mycological cure (76% compared to up to 42% for competitors) and a significantly higher total cure rate than the vehicle, without manifesting any serious side effects. The MOB-015 topical terbinafine formulation allows effective terbinafine concentrations to permeate the nail and nail bed, circumventing the risk of systemic exposure linked with oral terbinafine treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What Parameters Are Used to Define the Onychomycosis Treatment Market?

Onychomycosis treatment refers to the medical interventions and approaches used to manage and cure onychomycosis, a fungal infection that affects the nails, including both the fingernails and toenails. Treating onychomycosis typically involves a combination of topical and oral antifungal medications and preventive measures to reduce the risk of recurrence.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Forecast for the Onychomycosis Treatment Market from 2024 to 2025?#_x000D_

The market size for onychomycosis treatment has experienced significant growth lately. It is expected to rise from $3.65 billion in 2024 to reach $3.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The expansion during the historic period is likely due to various factors such as an increase in fungal infections, an aging population, heightened public awareness, a surge in onychomycosis cases, and higher disposable incomes._x000D_

_x000D_

#What Is the Projected Market Size of the Onychomycosis Treatment Market?#_x000D_

Expectations are high for a robust expansion in the onychomycosis treatment market in the coming years. The industry is projected to burgeon to a size of $5.09 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. The forecasted growth can be credited to multiple factors, such as the aging global population, the rise of telemedicine, the advent of combination therapy strategies, easier access to healthcare, alterations in lifestyle choices, environmental aspects, and an increasing proportion of diabetes patients. The significant trends anticipated during this forecast period are developments in dermatology, innovative approaches to drug delivery, personalized therapeutic treatment methods, advances in topical treatments, emerging digital health solutions, and laser therapy techniques._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp_x000D_

_x000D_

#Who are the Major Competitors in the Onychomycosis Treatment Market Outlook?#_x000D_

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited._x000D_

_x000D_

#What Is Fueling Growth in the Onychomycosis Treatment Market?#_x000D_

The growth of the onychomycosis treatment market is laden with an expected surge due to the rising incidences of fungal infections. These infections are microbial diseases triggered by varying types of fungi resulting in different conditions or affecting various body parts. Onychomycosis, a fungal infection of the nails, is usually treated with oral or topical antifungal medications to eradicate the fungi and promote healthy nail growth. For example, in September 2023, the UK Health Security Agency reported 2,265 cases of bloodstream infections triggered by yeast in England in 2022, as quoted by the SGSS. The overall episode rate of bloodstream infections due to yeast slightly increased to 4.0 per 100,000 people from 3.8 per 100,000 in 2021. Candida albicans (40%), formerly Candida glabrata or Nakaseomyces glabratus (29%), and Candida parapsilosis (13%) were the most frequently identified yeast species in blood specimens. As such, the escalating number of fungal infections is propelling the onychomycosis treatment market’s growth. Further driving the growth of the onychomycosis treatment market is the elevated prevalence of diabetes. This chronic health issue, typified by heightened blood glucose levels, increases the odds of encountering onychomycosis, enhances infection susceptibility, and decelerates the healing process. Topical and laser therapies are instrumental to avoid complications and enhance foot health, hence mitigating the likelihood of ensuing infections. As per the British Diabetic Association (Diabetes UK), around 4.4 million people in the UK were diagnosed with diabetes in 2022-23, a statistic reported in May 2024. Among these cases, about 8% were identified as Type 1 diabetes, whereas about 90% were Type 2 diabetes. The remaining 2% comprises other less prevalent forms of diabetes. Consequently, the growing prevalence of diabetes acts as a major propellant for the onychomycosis treatment market’s expansion._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp_x000D_

_x000D_

#Which Onychomycosis Treatment Market Segments Are Growing the Fastest?#_x000D_

The onychomycosis treatment market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types_x000D_

2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy_x000D_

3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above_x000D_

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels_x000D_

_x000D_

#Which Industry Trends Are Shaping the Future of the Onychomycosis Treatment Market?#_x000D_

To maintain their competitive advantage in the onychomycosis treatment market, key players like Moberg Pharma AB are concentrating on the development and approval of innovative products such as MOB-015. In June 2023, for example, the pharmaceutical company, based in Sweden, obtained authorization for MOB-015 in the European Union. This approval, the first of its kind globally for this innovative onychomycosis treatment, allows for its use in treating mild to moderate nail fungal infections in adults. The two Phase 3 trials that facilitated approval demonstrated a significantly better mycological cure rate (76% vs. 42% maximum for counterparts) and a noticeable overall cure rate for MOB-015, with no severe side effects. The product, a topical terbinafine formulation, delivers effective terbinafine concentrations to the nail and nail bed, reducing the risk of systemic exposure linked with oral terbinafine therapy._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report_x000D_

_x000D_

#Which Countries Are Leading the Onychomycosis Treatment Market?#_x000D_

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the onychomycosis treatment market, and how is it changing globally?_x000D_

2. Who are the major companies in the onychomycosis treatment market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the onychomycosis treatment market right now?_x000D_

4. Which products or customer segments are growing the most in the onychomycosis treatment market?_x000D_

5. What factors are helping or slowing down the growth of the onychomycosis treatment market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theOnychomycosis Treatment Market?

The rise in fungal infections is anticipated to boost the onychomycosis treatment market’s expansion. Fungal infections are microbial illnesses caused by a variety of fungi that affect various parts of the body or induce certain conditions. Onychomycosis, a fungal nail infection, is generally treated with oral or topical antifungal medications to eradicate the fungus and promote healthy nail growth. For example, the UK Health Security Agency reported 2,265 cases of bloodstream infections (BSI) due to yeast in England in 2022, according to data from September 2023. The incidence rate of BSI as a result of yeast increased marginally to 4.0 per 100,000 population from 3.8 per 100,000 in 2021. The most frequently identified yeast species in blood samples were Candida albicans (40%), Nakaseomyces glabratus (also known as Candida glabrata, 29%), and Candida parapsilosis (13%). Thus, the rise in fungal infections is stimulating the onychomycosis treatment market’s growth.

Diabetes Prevalence is Fuelling the Onychomycosis Treatment Market’s Growth

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

#What is the Anticipated CAGR of theOnychomycosis Treatment Market, and What Factors Will Drive It?

The market for onychomycosis treatments has seen robust growth in recent years. The market size will expand from $3.65 billion in 2024 to $3.92 billion in 2025, registering a compound annual growth rate (CAGR) of 7.4%. The historical growth can be credited to an uptick in fungal infections, an aging demographic, heightened public awareness, an increase in onychomycosis cases, and growth in disposable income.

There is an expectation for the onychomycosis treatment market size to experience robust growth in the upcoming years. Predictions have placed its value at $5.09 billion come 2029, with a compound annual growth rate (CAGR) of 6.7%. The predicted growth in the stated forecast period can be linked to several factors. These include an aging demographic, the proliferation of telemedicine, the advent of combination therapies, improved access to healthcare, lifestyle and environmental changes, and a rise in diabetes prevalence. Key trends for the forecast period encompass progress in dermatology, innovation in drug delivery, bespoke treatment plans, advancements in topical treatments, integration of digital health solutions and the advent of laser therapy.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

Which Upcoming Market Trends and Innovations Are Set to Influence theOnychomycosis Treatment Market’s Path Forward?

In the onychomycosis treatment market, key players are focusing their efforts on the development and approval of fresh products like MOB-015 to secure a market advantage. For example, Moberg Pharma AB, a pharmaceutical firm based in Sweden, gained European Union approval for MOB-015 in June 2023. This approval, intended for treating mild to moderate nail fungal infections in adults, represents the innovative onychomycosis drug’s inaugural authorization for global marketing. The approval of MOB-015 was supported by two Phase 3 trials which showcased a better mycological cure rate (76% versus a maximum of 42% for comparators) and a significantly higher total cure rate than the control group, without any severe side effects occurring. MOB-015, a topical terbinafine formulation, ensures effective terbinafine concentrations reach the nail and nail bed, eliminating the systemic exposure risk associated with orally administered terbinafine treatment.

Who Are the Dominant Market Players Pushing the Boundaries of theOnychomycosis Treatment Market?

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What Are the Core Segments of the Onychomycosis Treatment Market, and How Do They Contribute to Growth?

The onychomycosis treatment market covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types

2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy

3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

What Regions Are Dominating the Onychomycosis Treatment Market Growth?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Onychomycosis Treatment Market 2025, By The Business Research Company:

Biopharmaceuticals Contract Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Mid-Size Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mid-size-pharmaceuticals-global-market-report

Generic Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the onychomycosis treatment market grown over the years?

The onychomycosis treatment market has seen significant growth and is projected to increase from $3.65 billion in 2024 to $3.92 billion in 2025, with a CAGR of 7.4%. Key factors contributing to this expansion include a higher prevalence of fungal infections, an aging population, greater public awareness, increasing disposable incomes, and the rising occurrence of onychomycosis.

What Is the forecasted market size and growth rate for the onychomycosis treatment market?

The onychomycosis treatment market is projected for steady expansion, reaching $5.09 billion by 2029 at a CAGR of 6.7%. Growth drivers include aging populations, telemedicine expansion, combination therapies, healthcare accessibility, lifestyle changes, and diabetes prevalence. Key trends involve dermatological advancements, drug delivery innovations, personalized treatments, topical treatment improvements, digital health solutions, and laser therapy.

Get your onychomycosis treatment market report here!

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What are the major factors driving growth in the onychomycosis treatment market?

The rising incidence of fungal infections is expected to propel the onychomycosis treatment market. Fungal infections, caused by various fungi, can affect different body parts, including nails. Onychomycosis treatments involve oral and topical antifungal medications to eliminate infections and restore nail health. In September 2023, the UK Health Security Agency reported 2,265 cases of yeast-related bloodstream infections in England in 2022, with an incidence rate increase from 3.8 to 4.0 per 100,000 people. The most common yeast species detected were Candida albicans (40%), Nakaseomyces glabratus (29%), and Candida parapsilosis (13%). This rise in fungal infections is driving the onychomycosis treatment market.

What key areas define the segmentation of the global onychomycosis treatment Market?

The onychomycosis treatment market covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types

2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy

3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

What are the top market players propelling the growth of the onychomycosis treatment industry?

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

What are the key trends shaping the future of the onychomycosis treatment market?

Leading businesses in the onychomycosis treatment market are striving for competitive advantage by developing and gaining federal approval for new products, like MOB-015. In June 2023, for instance, Moberg Pharma AB, a Swedish pharmaceutical firm, secured European Union approval for MOB-015, designed to treat mild to moderate nail fungal infections in adults. This green light by the European Union signifies the first global marketing permission for this innovative onychomycosis drug. Evidence from two Phase 3 trials that backed the approval of MOB-015 showed an enhanced mycological cure (76% vs. up to 42% for other comparables) and a remarkably higher total cure rate than the vehicle, with no serious side effects. The topical terbinafine formula, MOB-015, ensures efficient terbinafine concentrations reach the nail and nail bed without the systemic exposure risk that oral terbinafine treatment carries.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

What regions are dominating the onychomycosis treatment market growth?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Biopharmaceuticals Contract Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Mid-Size Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mid-size-pharmaceuticals-global-market-report

Generic Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Onychomycosis Treatment Market, and How Will It Perform by 2034?

The market for the treatment of onychomycosis has seen significant growth in the past few years. Predictions indicate an increase in market size from $3.65 billion in 2024 to $3.92 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.4%. This escalation during the historic period is owing to the rise in fungal infections, a growing elderly population, greater public consciousness, an increased occurrence of onychomycosis, and higher levels of disposable income.

The market for onychomycosis treatment is predicted to experience significant expansion in the coming years, with expectations to reach a market size of $5.09 billion by 2029 at a compound annual growth rate (CAGR) of 6.7%. Several factors could contribute to this projected growth, such as an aging demographic, the proliferation of telemedicine, combination therapies, an increase in healthcare accessibility, lifestyle changes, environmental influences, and a rise in diabetes prevalence. Key trends anticipated during this forecast period encompass advancements in dermatology, innovations in drug delivery, individualized treatment strategies, progress in topical treatments, digital health solutions, and laser therapy.

What Industry-Specific Factors Are Fueling the Growth of the Onychomycosis Treatment Market?

The rise in fungal infections is anticipated to spur the expansion of the onychomycosis treatment market. These infections are caused by a variety of fungi, which affect different areas of the body and lead to certain conditions. Oral antifungal medications or topical antifungal solutions are commonly used to treat Onychomycosis (a nail infection caused by fungi). For instance, as reported by the UK Health Security Agency in September 2023, in 2022, England documented 2,265 cases of yeast-induced bloodstream infections (BSI). The overall incidence rate of BSI due to yeast slightly increased to 4.0 per 100,000 population, a slight rise from 3.8 per 100,000 in 2021. The three most frequently found yeast species in blood samples were Candida albicans at 40%, Nakaseomyces glabratus (previously known as Candida glabrata) at 29%, and Candida parapsilosis at 13%. Therefore, the mounting prevalence of fungal infections is a driving force for the growth of the onychomycosis treatment market. Onychomycosis Treatment Market Driver: Increasing Diabetes Incidence Fuels Onychomycosis Treatment Market Expansion

Request Your Free Onychomycosis Treatment Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Onychomycosis Treatment Market?

Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

What Are the Key Emerging Trends in the Onychomycosis Treatment Market for the Next Decade?

Leading businesses in the onychomycosis treatment market are striving for competitive advantage by developing and gaining federal approval for new products, like MOB-015. In June 2023, for instance, Moberg Pharma AB, a Swedish pharmaceutical firm, secured European Union approval for MOB-015, designed to treat mild to moderate nail fungal infections in adults. This green light by the European Union signifies the first global marketing permission for this innovative onychomycosis drug. Evidence from two Phase 3 trials that backed the approval of MOB-015 showed an enhanced mycological cure (76% vs. up to 42% for other comparables) and a remarkably higher total cure rate than the vehicle, with no serious side effects. The topical terbinafine formula, MOB-015, ensures efficient terbinafine concentrations reach the nail and nail bed without the systemic exposure risk that oral terbinafine treatment carries.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

Which Key Market Segments Comprise the Onychomycosis Treatment Market and Drive Its Revenue Growth?

The onychomycosis treatment market covered in this report is segmented –

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types

2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy

3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Which Regions Are Making a Mark in the Onychomycosis Treatment Market Growth?

North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Onychomycosis Treatment Market Categorized and Defined in the Industry?

Onychomycosis treatment refers to the medical interventions and approaches used to manage and cure onychomycosis, a fungal infection that affects the nails, including both the fingernails and toenails. Treating onychomycosis typically involves a combination of topical and oral antifungal medications and preventive measures to reduce the risk of recurrence.

Browse Through More Similar Reports By The Business Research Company:

Biopharmaceuticals Contract Manufacturing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report

Mid-Size Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mid-size-pharmaceuticals-global-market-report

Generic Pharmaceuticals Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: